8-K Announcements
6Material company update
Apr 28, 2026·SEC
Material company update
Apr 28, 2026·SEC
Material company update
Apr 20, 2026·SEC
National Research Corporation(NRC)Earnings, Financials & Key Ratios
NRC•NASDAQ
37.6× P/E·Price updated May 30, 2026
AboutNational Research Corporation provides analytics and insights that facilitate measurement and enhancement of the patient and employee experience in the United States and Canada. Its portfolio of subscription-based solutions provides actionable information and analysis to healthcare organizations across a range of mission-critical, constituent-related elements, including patient experience, service recovery, care transitions, health risk assessments, employee engagement, reputation management, and brand loyalty. The company also offers market insights solutions that allow the tracking of awareness, perception, and consistency of healthcare brands; assessment of competitive differentiators; and enhanced segmentation tools to evaluate needs, wants, and behaviors of communities through real-time competitive assessments and enhanced segmentation tools. In addition, it provides experience solutions, such as patient and resident experience, workforce engagement, health risk assessments, transitions, and improvement tools. Further, the company offers health risk assessment solutions that enable clients to segment populations and manage care for those who are most at risk, engage individuals, enhance preventative care, and manage wellness programs; and transitions solutions, which enable organizations to identify and manage high-risk patients to reduce readmissions, enhance patient satisfaction and support safe care transitions. Additionally, it provides transparency solutions that allow healthcare organizations to share picture of their organization and ensure content informs in consumer decision-making; and governance solutions for not-for-profit hospital and health system boards of directors, executives, and physician leadership. The company serves integrated health systems, post-acute providers, and payer organizations. National Research Corporation was founded in 1981 and is headquartered in Lincoln, Nebraska.Show more
- Revenue$137M-4.0%
- EBITDA$30M-26.7%
- Net Income$12M-53.2%
- EPS (Diluted)0.52-50.0%
- Gross Margin56.33%-6.4%
- EBITDA Margin21.99%-23.7%
- Operating Margin16.44%-33.2%
- Net Margin8.44%-51.3%
- ROE51.24%-17.0%
- ROIC18.79%-38.5%
- Debt/Equity5.65+174.4%
- Interest Coverage4.75-65.1%
NRC Key Insights
National Research Corporation (NRC) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Excellent 3Y average ROE of 54.7%
- ✓High quality earnings: Operating CF exceeds net income
- ✓Healthy dividend yield of 2.5%
- ✓Share count reduced 5.7% through buybacks
- ✓Healthy 5Y average net margin of 18.6%
- ✓Efficient asset utilization: 1.0x turnover
✗Weaknesses
- ✗High debt to equity ratio of 5.6x
- ✗Profits declining 20.8% over 5 years
- ✗Expensive at 31.3x book value
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when NRC posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
NRC Price & Volume
National Research Corporation (NRC) stock price & volume — 10-year historical chart
Loading chart...
NRC Growth Metrics
National Research Corporation (NRC) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years2.99%
5 Years0.61%
3 Years-3.22%
TTM-1.88%
Profit CAGR
10 Years-4.09%
5 Years-20.81%
3 Years-28.55%
TTM-62.68%
EPS CAGR
10 Years2.41%
5 Years-18.54%
3 Years-25.74%
TTM-61.39%
Return on Capital
10 Years42.65%
5 Years38.95%
3 Years35.12%
Last Year23.18%
NRC Recent Earnings
National Research Corporation (NRC) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 0/12 qtrs (0%)●Beat Revenue 0/12 qtrs (0%)
Q2 2026Latest
Apr 28, 2026EPS
$0.21
Revenue
$35M
Q1 2026
Feb 3, 2026EPS
$0.16
Revenue
$35M
Q4 2025
Oct 27, 2025EPS
$0.23
Revenue
$35M
Q3 2025
Jul 28, 2025EPS
$0.28
Revenue
$34M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 28, 2026 | $0.21 | $35M |
| Q1 2026 | Feb 3, 2026 | $0.16 | $35M |
| Q4 2025 | Oct 27, 2025 | $0.23 | $35M |
| Q3 2025 | Jul 28, 2025 | $0.28 | $34M |
Based on last 12 quarters of dataView full earnings history →
NRC Peer Comparison
National Research Corporation (NRC) competitors in Healthcare Data, Analytics and AI — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 SATS | 37.23B | 129.19 | -2.56 | -5.18% | -157.17% | -243.07% | 5.33 | |
 FORR | 135.19M | 7.05 | -1.12 | -8.23% | -13.74% | -39.22% | 0.57 | |
 CSGP | 13.65B | 32.20 | 1939.76 | 18.67% | 0.74% | 0.3% | 0.14 | |
 MORN | 6.92B | 182.02 | 20.52 | 7.49% | 30.01% | 1.15 | ||
 QNST | 719.22M | 12.52 | 155.14 | 78.27% | 5.53% | 23.85% | 0.04 | |
 HCAT | 101.97M | 1.38 | -0.54 | 1.48% | -87.69% | -99.78% | 0.70 | |
 PINC | 2.34B | 28.26 | 128.45 | -10.86% | -2.42% | -1.59% | 0.18 | |
 HQY | 7.38B | 87.99 | 35.77 | 9.47% | 17.25% | 10.94% | 0.48 |
Compare NRC vs Peers
National Research Corporation (NRC) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
NRC Income Statement
National Research Corporation (NRC) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 117.56M | 119.69M | 127.98M | 133.28M | 147.95M | 151.57M | 148.58M | 143.06M | 137.39M | 138.64M |
Revenue Growth % | 7.47% | 1.81% | 6.93% | 4.14% | 11.01% | 2.44% | -1.97% | -3.72% | -3.96% | -1.88% |
Cost of Goods Sold | 49.07M | 47.58M | 46.44M | 49.19M | 52.35M | 57.05M | 56.02M | 56.93M | 59.99M | 61.21M |
COGS % of Revenue | 41.74% | 39.75% | 36.28% | 36.91% | 35.38% | 37.64% | 37.7% | 39.8% | 43.67% | - |
Gross Profit | 68.49M▲ 0% | 72.11M▲ 5.3% | 81.55M▲ 13.1% | 84.09M▲ 3.1% | 95.6M▲ 13.7% | 94.52M▼ 1.1% | 92.56M▼ 2.1% | 86.13M▼ 7.0% | 77.39M▼ 10.1% | 77.43M▲ 0% |
Gross Margin % | 58.26% | 60.25% | 63.72% | 63.09% | 64.62% | 62.36% | 62.3% | 60.2% | 56.33% | 55.85% |
Gross Profit Growth % | 7.34% | 5.28% | 13.09% | 3.12% | 13.69% | -1.13% | -2.07% | -6.96% | -10.14% | - |
Operating Expenses | 34.27M | 36.83M | 38.51M | 41.41M | 45.33M | 47.98M | 52.52M | 50.93M | 54.8M | 57.87M |
OpEx % of Revenue | 29.15% | 30.78% | 30.09% | 31.07% | 30.64% | 31.65% | 35.35% | 35.6% | 39.89% | - |
Selling, General & Admin | 29.69M | 31.37M | 32.97M | 34.44M | 38.96M | 42.7M | 46.58M | 44.91M | 54.8M | 57.87M |
SG&A % of Revenue | 25.25% | 26.21% | 25.76% | 25.84% | 26.33% | 28.17% | 31.35% | 31.39% | 39.89% | - |
Research & Development | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
R&D % of Revenue | - | - | - | - | - | - | - | - | - | - |
Other Operating Expenses | 50K | 885K | 5.54M | 7.03M | 6.37M | 5.28M | 5.94M | 6.02M | 0 | 0 |
Operating Income | 34.22M▲ 0% | 35.27M▲ 3.1% | 43.03M▲ 22.0% | 42.68M▼ 0.8% | 50.27M▲ 17.8% | 46.54M▼ 7.4% | 40.05M▼ 14.0% | 35.19M▼ 12.1% | 22.59M▼ 35.8% | 19.56M▲ 0% |
Operating Margin % | 29.11% | 29.47% | 33.63% | 32.02% | 33.98% | 30.71% | 26.95% | 24.6% | 16.44% | 14.11% |
Operating Income Growth % | 9.69% | 3.09% | 22% | -0.83% | 17.79% | -7.41% | -13.96% | -12.11% | -35.81% | - |
EBITDA | 38.8M | 40.74M | 48.57M | 50.18M | 56.64M | 51.82M | 45.94M | 41.22M | 30.21M | 27.81M |
EBITDA Margin % | 33.01% | 34.04% | 37.95% | 37.65% | 38.28% | 34.19% | 30.92% | 28.81% | 21.99% | 20.06% |
EBITDA Growth % | 9.55% | 4.98% | 19.24% | 3.31% | 12.88% | -8.52% | -11.34% | -10.29% | -26.69% | -32.4% |
D&A (Non-Cash Add-back) | 4.59M | 5.46M | 5.54M | 7.5M | 6.37M | 5.28M | 5.9M | 6.02M | 7.62M | 8.25M |
EBIT | 34.22M | 35.27M | 43.03M | 43.28M | 50.29M | 44.02M | 40.09M | 35.28M | 22.61M | 19.55M |
Net Interest Income | 14K | -1.45M | -2.05M | -1.79M | -1.65M | -1.04M | -42K | -2.47M | -4.65M | -4.99M |
Interest Income | 96K | 62K | 37K | 18K | 14K | 168K | 820K | 125K | 111K | 127K |
Interest Expense | 82K | 1.51M | 2.09M | 1.81M | 1.67M | 1.21M | 862K | 2.6M | 4.76M | 5.12M |
Other Income/Expense | 64K | -566K | -2.52M | -1.21M | -1.65M | -3.73M | -83K | -2.5M | -4.75M | -5.06M |
Pretax Income | 34.28M▲ 0% | 34.71M▲ 1.2% | 40.52M▲ 16.7% | 41.47M▲ 2.3% | 48.62M▲ 17.3% | 42.81M▼ 11.9% | 39.96M▼ 6.7% | 32.69M▼ 18.2% | 17.84M▼ 45.4% | 14.5M▲ 0% |
Pretax Margin % | 29.16% | 29% | 31.66% | 31.11% | 32.86% | 28.25% | 26.9% | 22.85% | 12.99% | 10.46% |
Income Tax | 11.34M | 4.66M | 8.11M | 4.21M | 11.15M | 11.02M | 8.99M | 7.91M | 6.24M | 5.47M |
Effective Tax Rate % | 33.08% | 13.43% | 20.02% | 10.15% | 22.94% | 25.73% | 22.5% | 24.19% | 34.99% | 37.7% |
Net Income | 22.94M▲ 0% | 30.05M▲ 31.0% | 32.41M▲ 7.9% | 37.26M▲ 15.0% | 37.47M▲ 0.6% | 31.8M▼ 15.1% | 30.97M▼ 2.6% | 24.78M▼ 20.0% | 11.6M▼ 53.2% | 9.03M▲ 0% |
Net Margin % | 19.52% | 25.1% | 25.32% | 27.96% | 25.32% | 20.98% | 20.84% | 17.32% | 8.44% | 6.52% |
Net Income Growth % | 11.82% | 30.96% | 7.85% | 14.98% | 0.55% | -15.12% | -2.61% | -19.98% | -53.19% | -62.68% |
Net Income (Continuing) | 22.94M | 30.05M | 32.41M | 37.26M | 37.47M | 31.8M | 30.97M | 24.78M | 11.6M | 9.04M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | 0.52▲ 0% | 1.07▲ 105.8% | 1.26▲ 17.8% | 1.45▲ 15.1% | 1.46▲ 0.7% | 1.27▼ 13.0% | 1.25▼ 1.6% | 1.04▼ 16.8% | 0.52▼ 50.0% | 0.41▲ 0% |
EPS Growth % | 8.33% | 105.77% | 17.76% | 15.08% | 0.69% | -13.01% | -1.57% | -16.8% | -50% | -61.39% |
EPS (Basic) | 0.54 | 1.11 | 1.30 | 1.48 | 1.47 | 1.28 | 1.26 | 1.05 | 0.52 | - |
Diluted Shares Outstanding | 25.23M | 28.08M | 25.65M | 25.7M | 25.64M | 25.05M | 24.67M | 23.74M | 22.4M | 21.91M |
Basic Shares Outstanding | 24.28M | 27.09M | 24.81M | 25.17M | 25.42M | 24.92M | 24.54M | 23.72M | 22.38M | 21.8M |
Dividend Payout Ratio | 73.52% | 56.11% | 96.58% | 28.23% | 24.45% | 65.92% | 117.42% | 46.21% | 94.64% | - |
NRC Balance Sheet
National Research Corporation (NRC) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 52.26M | 28.06M | 29.16M | 54.11M | 73.71M | 43.72M | 24.36M | 19.6M | 20.21M | 19.98M |
Cash & Short-Term Investments | 34.73M | 12.99M | 13.52M | 34.69M | 54.36M | 25.03M | 6.65M | 4.23M | 4.14M | 2.55M |
Cash Only | 34.73M | 12.99M | 13.52M | 34.69M | 54.36M | 25.03M | 6.65M | 4.23M | 4.14M | 2.55M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 15.18M | 11.97M | 11.81M | 15.47M | 14.58M | 15.3M | 12.62M | 11.2M | 11.11M | 10.83M |
Days Sales Outstanding | 47.13 | 36.52 | 33.68 | 42.36 | 35.97 | 36.84 | 31.01 | 28.56 | 29.51 | 31.35 |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
Other Current Assets | 410K | 519K | 1.79M | 1.31M | 883K | 1.01M | 856K | 692K | 4.96M | 6.6M |
Total Non-Current Assets | 75.06M | 79.62M | 81.53M | 79.31M | 83.83M | 86.75M | 98.08M | 112.94M | 114.67M | 114.58M |
Property, Plant & Equipment | 12.36M | 14.15M | 15.16M | 13.03M | 13.37M | 17.8M | 30.27M | 39.9M | 40.47M | 40.3M |
Fixed Asset Turnover | 9.51x | 8.46x | 8.44x | 10.23x | 11.07x | 8.51x | 4.91x | 3.59x | 3.39x | 3.37x |
Goodwill | 58.02M | 57.83M | 57.94M | 57.26M | 61.61M | 61.61M | 61.61M | 66.15M | 66.15M | 66.15M |
Intangible Assets | 2.76M | 2.1M | 1.73M | 1.41M | 1.79M | 1.61M | 1.47M | 2.62M | 0 | 0 |
Long-Term Investments | 0 | -6.28M | 0 | 0 | 0 | 0 | 0 | 1.3M | 0 | 0 |
Other Non-Current Assets | 4.68M | 7.64M | 6.71M | 7.61M | 7.05M | 5.7M | 4.73M | 2.98M | 8.04M | 8.12M |
Total Assets | 127.32M▲ 0% | 107.68M▼ 15.4% | 110.69M▲ 2.8% | 133.42M▲ 20.5% | 157.54M▲ 18.1% | 130.46M▼ 17.2% | 122.44M▼ 6.2% | 132.54M▲ 8.3% | 134.88M▲ 1.8% | 134.56M▲ 0% |
Asset Turnover | 0.92x | 1.11x | 1.16x | 1.00x | 0.94x | 1.16x | 1.21x | 1.08x | 1.02x | 1.01x |
Asset Growth % | 5.55% | -15.42% | 2.79% | 20.54% | 18.08% | -17.19% | -6.15% | 8.25% | 1.76% | 23% |
Total Current Liabilities | 32.31M | 46.76M | 38.16M | 31.68M | 40.39M | 33.42M | 36.2M | 35.86M | 36.62M | 38.47M |
Accounts Payable | 593K | 613K | 1.28M | 1.09M | 1.94M | 1.15M | 1.3M | 1.19M | 4.07M | 4.81M |
Days Payables Outstanding | 4.41 | 4.7 | 10.05 | 8.13 | 13.55 | 7.38 | 8.48 | 7.65 | 24.74 | 30.8 |
Short-Term Debt | 1.07M | 3.67M | 5.13M | 5.01M | 5.24M | 5.32M | 7.82M | 4.79M | 4.01M | 4.01M |
Deferred Revenue (Current) | 16.88M | 16.24M | 16.35M | 15.59M | 17.21M | 15.2M | 14.83M | 15.79M | 16.2M | 66.81M |
Other Current Liabilities | 14.21M | 39.89M | 8.94M | 3.53M | 8.85M | 7.19M | 8.08M | 541K | 5.12M | 12.45M |
Current Ratio | 1.62x | 0.60x | 0.76x | 1.71x | 1.82x | 1.31x | 0.67x | 0.55x | 0.55x | 0.55x |
Quick Ratio | 1.62x | 0.60x | 0.76x | 1.71x | 1.82x | 1.31x | 0.67x | 0.55x | 0.55x | 0.55x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | 0.55 |
Total Non-Current Liabilities | 4.96M | 41.84M | 39.64M | 37.43M | 31.82M | 25.01M | 37.28M | 65.4M | 84.27M | 82.59M |
Long-Term Debt | 0 | 34.18M | 29.8M | 26.55M | 22.27M | 17.69M | 29.47M | 57.9M | 75.02M | 74.02M |
Capital Lease Obligations | 0 | 0 | 1.7M | 1.67M | 1.17M | 372K | 1.67M | 1.17M | 0 | 0 |
Deferred Tax Liabilities | 4.03M | 6.28M | 7.4M | 7.26M | 7M | 5.27M | 4.14M | 3.53M | 0 | 6.95M |
Other Non-Current Liabilities | 935K | 1.39M | 746K | 1.94M | 1.38M | 1.67M | 2M | 2.59M | 9.25M | 8.58M |
Total Liabilities | 37.27M | 88.6M | 77.79M | 69.11M | 72.2M | 58.43M | 73.48M | 101.25M | 120.89M | 121.06M |
Total Debt | 1.07M | 3.67M | 36.62M | 33.24M | 28.68M | 23.39M | 38.96M | 64.41M | 79.03M | 78.03M |
Net Debt | -33.67M | -9.32M | 23.11M | -1.45M | -25.68M | -1.64M | 32.3M | 60.18M | 74.9M | 75.48M |
Debt / Equity | 0.01x | 0.19x | 1.11x | 0.52x | 0.34x | 0.32x | 0.80x | 2.06x | 5.65x | 5.65x |
Debt / EBITDA | 0.03x | 0.09x | 0.75x | 0.66x | 0.51x | 0.45x | 0.85x | 1.56x | 2.62x | 2.81x |
Net Debt / EBITDA | -0.87x | -0.23x | 0.48x | -0.03x | -0.45x | -0.03x | 0.70x | 1.46x | 2.48x | 2.48x |
Interest Coverage | 417.30x | 23.31x | 20.58x | 23.87x | 30.17x | 36.41x | 46.50x | 13.60x | 4.75x | 3.82x |
Total Equity | 90.04M▲ 0% | 19.08M▼ 78.8% | 32.89M▲ 72.4% | 64.31M▲ 95.5% | 85.34M▲ 32.7% | 72.03M▼ 15.6% | 48.95M▼ 32.0% | 31.28M▼ 36.1% | 13.99M▼ 55.3% | 13.49M▲ 0% |
Equity Growth % | 8.74% | -78.81% | 72.36% | 95.53% | 32.69% | -15.59% | -32.04% | -36.1% | -55.28% | -215.4% |
Book Value per Share | 3.57 | 0.68 | 1.28 | 2.50 | 3.33 | 2.88 | 1.98 | 1.32 | 0.62 | 0.62 |
Total Shareholders' Equity | 90.04M | 19.08M | 32.89M | 64.31M | 85.34M | 72.03M | 48.95M | 31.28M | 13.99M | 13.49M |
Common Stock | 30K | 30K | 30K | 31K | 31K | 31K | 31K | 31K | 32K | 32K |
Retained Earnings | 77.57M | -106.34M | -93.36M | -61.38M | -36.11M | -25.18M | -30.53M | -17.06M | -17.3M | -17.68M |
Treasury Stock | -36.95M | -29M | -33.73M | -43.73M | -50.15M | -78.27M | -98.76M | -131.93M | -152.62M | -154.48M |
Accumulated OCI | -1.64M | -2.92M | -2.21M | -2.4M | -2.38M | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
NRC Cash Flow Statement
National Research Corporation (NRC) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | 28.09M | 39.85M | 40.92M | 40.64M | 46.34M | 36.27M | 38.11M | 34.63M | 26.45M | 26.45M |
Operating CF Margin % | 23.9% | 33.29% | 31.97% | 30.49% | 31.32% | 23.93% | 25.65% | 24.2% | 19.25% | - |
Operating CF Growth % | 4.65% | 41.85% | 2.68% | -0.69% | 14.05% | -21.75% | 5.1% | -9.15% | -23.61% | -50.12% |
Net Income | 22.94M | 30.05M | 32.41M | 37.26M | 37.47M | 31.8M | 30.97M | 24.78M | 11.6M | 9.03M |
Depreciation & Amortization | 4.59M | 5.46M | 5.54M | 7.5M | 6.37M | 5.28M | 5.9M | 6.02M | 7.62M | 8.25M |
Stock-Based Compensation | 1.84M | 1.51M | 1.22M | 680K | 623K | 1.2M | 935K | 284K | 3.31M | 4.75M |
Deferred Taxes | -684K | 1.19M | 1.14M | 51K | 33K | -1.24M | -717K | -406K | 2.45M | 629K |
Other Non-Cash Items | 207K | 186K | -6K | -248K | 7K | 2.58M | -102K | 100K | 545K | 255K |
Working Capital Changes | -806K | 1.45M | 616K | -4.61M | 1.84M | -3.35M | 1.02M | 3.84M | 916K | 4.07M |
Change in Receivables | -2.46M | 2.77M | 311K | -2.27M | 343K | -733K | 2.08M | 1.76M | -53K | 494K |
Change in Inventory | 1.32M | -1.4M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 12K | -39K | 647K | -247K | 4K | -589K | 184K | -108K | 170K | 485K |
Cash from Investing | -6.12M | -5.97M | -4.66M | -3.72M | -8.51M | -9.84M | -15.78M | -20.28M | -10.71M | -9.55M |
Capital Expenditures | -4.82M | -5.97M | -4.66M | -3.98M | -5.51M | -9.84M | -15.78M | -15.45M | -10.71M | -9.55M |
CapEx % of Revenue | 4.1% | 4.99% | 3.64% | 2.99% | 3.73% | 6.49% | 10.62% | 10.8% | 7.79% | - |
Acquisitions | 0 | 0 | 0 | 0 | -3M | 0 | 0 | -4.83M | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | -1.55M | -5.97M | 0 | 260K | 0 | 0 | 1K | 0 | 0 | 0 |
Cash from Financing | -21.12M | -54.5M | -36.35M | -15.5M | -18.16M | -55.58M | -40.71M | -16.76M | -15.84M | -17.39M |
Debt Issued (Net) | -2.58M | 36.77M | -3.94M | -3.9M | -4.59M | -4.77M | 14.18M | 25.99M | 16.11M | 12.7M |
Equity Issued (Net) | -1.67M | -72.37M | 0 | 0 | -4.14M | -27.81M | -19.1M | -30.95M | -20.05M | -17.2M |
Dividends Paid | -16.87M | -16.86M | -31.3M | -10.52M | -9.16M | -20.96M | -36.37M | -11.45M | -10.98M | -11.83M |
Share Repurchases | -1.67M | -72.37M | 0 | 0 | -4.14M | -27.62M | -19.1M | -30.95M | -20.18M | -17.2M |
Other Financing | 0 | -2.04M | -1.1M | -1.09M | -275K | -2.04M | 576K | -359K | -923K | -1.05M |
Net Change in Cash | 1.71M▲ 0% | -21.74M▼ 1370.0% | 526K▲ 102.4% | 21.17M▲ 3925.3% | 19.67M▼ 7.1% | -29.34M▼ 249.1% | -18.37M▲ 37.4% | -2.42M▲ 86.8% | -94K▲ 96.1% | 45K▲ 0% |
Free Cash Flow | 23.27M▲ 0% | 33.88M▲ 45.6% | 36.26M▲ 7.0% | 36.65M▲ 1.1% | 40.83M▲ 11.4% | 26.43M▼ 35.3% | 22.33M▼ 15.5% | 19.18M▼ 14.1% | 15.74M▼ 17.9% | 17.43M▲ 0% |
FCF Margin % | 19.8% | 28.3% | 28.33% | 27.5% | 27.6% | 17.44% | 15.03% | 13.4% | 11.46% | 12.57% |
FCF Growth % | 1.76% | 45.56% | 7.04% | 1.08% | 11.4% | -35.27% | -15.5% | -14.14% | -17.9% | 16.68% |
FCF per Share | 0.92 | 1.21 | 1.41 | 1.43 | 1.59 | 1.06 | 0.91 | 0.81 | 0.70 | 0.70 |
FCF Conversion (FCF/Net Income) | 1.22x | 1.33x | 1.26x | 1.09x | 1.24x | 1.14x | 1.23x | 1.40x | 2.28x | 1.93x |
Interest Paid | 76K | 1.28M | 2.01M | 1.74M | 1.68M | 1.23M | 803K | 2.44M | 0 | 2.35M |
Taxes Paid | 12.83M | 2.63M | 6.95M | 5.22M | 10.64M | 12.23M | 8.93M | 8.22M | 0 | 3.45M |
NRC Key Ratios
National Research Corporation (NRC) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | 26.55% | 55.07% | 124.7% | 76.66% | 50.07% | 40.41% | 51.2% | 61.77% | 51.24% | 57.24% |
| Return on Invested Capital (ROIC) | 47.16% | 80.01% | 98.17% | 53.86% | 61.55% | 53.68% | 39.61% | 30.56% | 18.79% | 18.79% |
| Gross Margin | 58.26% | 60.25% | 63.72% | 63.09% | 64.62% | 62.36% | 62.3% | 60.2% | 56.33% | 55.85% |
| Net Margin | 19.52% | 25.1% | 25.32% | 27.96% | 25.32% | 20.98% | 20.84% | 17.32% | 8.44% | 6.52% |
| Debt / Equity | 0.01x | 0.19x | 1.11x | 0.52x | 0.34x | 0.32x | 0.80x | 2.06x | 5.65x | 5.65x |
| Interest Coverage | 417.30x | 23.31x | 20.58x | 23.87x | 30.17x | 36.41x | 46.50x | 13.60x | 4.75x | 3.82x |
| FCF Conversion | 1.22x | 1.33x | 1.26x | 1.09x | 1.24x | 1.14x | 1.23x | 1.40x | 2.28x | 1.93x |
| Revenue Growth | 7.47% | 1.81% | 6.93% | 4.14% | 11.01% | 2.44% | -1.97% | -3.72% | -3.96% | -1.88% |
Related:NRC Dividend History·NRC Revenue History·NRC Price History·NRC P/E History·NRC Financial Ratios·NRC Institutional Holders
NRC SEC Filings & Documents
National Research Corporation (NRC) SEC filings — annual & quarterly reports (10-K, 10-Q)
NRC Frequently Asked Questions
National Research Corporation (NRC) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
National Research Corporation (NRC) reported $138.6M in revenue for fiscal year 2025. This represents a 1000% increase from $12.6M in 1996.
National Research Corporation (NRC) saw revenue decline by 4.0% over the past year.
Yes, National Research Corporation (NRC) is profitable, generating $9.0M in net income for fiscal year 2025 (8.4% net margin).
Dividend & Returns
Yes, National Research Corporation (NRC) pays a dividend with a yield of 2.51%. This makes it attractive for income-focused investors.
National Research Corporation (NRC) has a return on equity (ROE) of 51.2%. This is excellent, indicating efficient use of shareholder capital.
National Research Corporation (NRC) generated $17.4M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.